Skip to main content
BLINKLAB LIMITED logo

BLINKLAB LIMITED — Investor Relations & Filings

Ticker · BB1 ISIN · AU0000322851 LEI · 529900BTGD6TA3TPLS56 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 164 across all filing types
Latest filing 2024-06-19 Director's Dealing
Country AU Australia
Listing ASX BB1

About BLINKLAB LIMITED

https://www.blinklab.org

BlinkLab Limited is a digital health technology company specializing in the development of smartphone-based diagnostic platforms for neurodevelopmental and neurodegenerative disorders. The company utilizes advanced computer vision and machine learning algorithms to transform standard smartphones into clinical-grade tools for neurological assessment. Its core technology focuses on the eyeblink conditioning paradigm, a well-established biomarker for brain function, to screen for conditions such as Autism Spectrum Disorder (ASD), ADHD, and schizophrenia. By enabling remote, objective, and scalable testing, BlinkLab aims to facilitate early intervention and continuous monitoring outside of traditional clinical settings. The platform is designed to provide healthcare professionals with data-driven insights to improve diagnostic accuracy and patient outcomes in the field of behavioral health and neurology.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 3 pages 814.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares acquired, disposed, and held after the change. The document is a formal notification of insider share transactions by a director, consistent with regulatory requirements for director dealings disclosures. It does not contain financial statements, earnings data, or management commentary. The document length is 4269 characters, which is typical for such notices. Therefore, this document fits the category of Director's Dealing (DIRS).
2024-06-19 English
Change of Director's Interest Notice 3 pages 805.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares acquired, disposed, and held, as well as the nature of the transaction (on-market purchase). The document is a formal notification of a director's personal share transactions, which aligns with the definition of Director's Dealing filings. The document length is 3709 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, audit report, or any other type of financial or regulatory filing. Therefore, the correct classification is Director's Dealing (DIRS).
2024-06-17 English
Change of Director's Interest Notice 3 pages 814.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares acquired, disposed, and held after the change. The document is a formal notification of insider share transactions by a director, consistent with regulatory requirements for disclosure of personal share dealings by company directors. It does not contain financial performance data, management discussion, or other report content. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 4276 characters, which is typical for such notices and not a report publication announcement or regulatory filing. Confidence is high due to clear match with the definition of Director's Dealing.
2024-06-17 English
Change of Director's Interest Notice 3 pages 787.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director and related parties, including dates, number of shares before and after the change, and nature of the transaction (on-market purchase). The document is a formal notification of a director's personal share transactions, which aligns with the definition of Director's Dealing filings. The document length is 4176 characters, which is consistent with a detailed notice rather than a brief announcement. There is no indication that this is an annual report, audit report, or any other type of financial or governance report. Therefore, the correct classification is Director's Dealing (DIRS).
2024-06-16 English
Change of Director's Interest Notice 3 pages 790.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares and options held before and after the change, the nature of the change (on-market purchase), and dates of the transactions. This type of document is a regulatory filing specifically reporting insider transactions by directors. It is not an annual report, earnings release, or any other financial report. The document length is 4393 characters, which is typical for such notices. Therefore, the correct classification is Director's Dealing (DIRS).
2024-06-16 English
BlinkLab starts Clinical Study with Bates College 4 pages 366.4KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement dated 6 June 2024 from BlinkLab Limited about starting a clinical study with Bates College to validate a smartphone-based diagnostic platform for Functional Neurological Disorder (FND). It includes background on the study, study design, comments from key personnel, terms of the collaboration agreement, and company background. There are no financial statements, earnings data, or regulatory filings typical of financial reports. The document is an announcement of a clinical study collaboration and partnership agreement, not a financial report, management change, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is a general corporate announcement about a clinical study and collaboration agreement. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2024-06-05 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.